Literature DB >> 28893920

Are SGLT2 Inhibitors Ready for Prime Time for CKD?

Roberto Pecoits-Filho1,2, Vlado Perkovic3,4.   

Abstract

Entities:  

Keywords:  Chronic; Renal Insufficiency; cardiovascular disease; chronic kidney disease; clinical trial; diabetes mellitus; sglt2 inhibitors

Mesh：

Substances：

Year:  2017        PMID： 28893920      PMCID： PMC5967433          DOI： 10.2215/CJN.07680717

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  9 in total

1.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

Review 2.  Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.

Authors:  Hiddo J L Heerspink; Bruce A Perkins; David H Fitchett; Mansoor Husain; David Z I Cherney
Journal:  Circulation       Date:  2016-07-28       Impact factor: 29.690

3.  Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.

Authors:  Hiddo J L Heerspink; Mehul Desai; Meg Jardine; Dainius Balis; Gary Meininger; Vlado Perkovic
Journal:  J Am Soc Nephrol       Date:  2016-08-18       Impact factor: 10.121

4.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

5.  Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.

Authors:  Sergei Petrykiv; C David Sjöström; Peter J Greasley; John Xu; Frederik Persson; Hiddo J L Heerspink
Journal:  Clin J Am Soc Nephrol       Date:  2017-03-16       Impact factor: 8.237

6.  Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.

Authors:  M Monami; C Nardini; E Mannucci
Journal:  Diabetes Obes Metab       Date:  2013-12-29       Impact factor: 6.577

7.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

Review 8.  Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.

Authors:  Jason H Y Wu; Celine Foote; Juuso Blomster; Tadashi Toyama; Vlado Perkovic; Johan Sundström; Bruce Neal
Journal:  Lancet Diabetes Endocrinol       Date:  2016-03-18       Impact factor: 32.069

Review 9.  Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.

Authors:  Mohsen Mazidi; Peyman Rezaie; Hong-Kai Gao; Andre Pascal Kengne
Journal:  J Am Heart Assoc       Date:  2017-05-25       Impact factor: 5.501
  9 in total
  13 in total

1.  Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.

Authors:  Brendon L Neuen; Toshiaki Ohkuma; Bruce Neal; David R Matthews; Dick de Zeeuw; Kenneth W Mahaffey; Greg Fulcher; Qiang Li; Meg Jardine; Richard Oh; Hiddo L Heerspink; Vlado Perkovic
Journal:  J Am Soc Nephrol       Date:  2019-09-17       Impact factor: 10.121

2.  Projecting ESRD Incidence and Prevalence in the United States through 2030.

Authors:  Keith P McCullough; Hal Morgenstern; Rajiv Saran; William H Herman; Bruce M Robinson
Journal:  J Am Soc Nephrol       Date:  2018-12-17       Impact factor: 10.121

Review 3.  Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).

Authors:  Raymond Vanholder; Steven Van Laecke; Griet Glorieux; Francis Verbeke; Esmeralda Castillo-Rodriguez; Alberto Ortiz
Journal:  Toxins (Basel)       Date:  2018-06-12       Impact factor: 4.546

Review 4.  Spotlight on Antidiabetic Agents with Cardiovascular or Renoprotective Benefits.

Authors:  Ruth Madievsky
Journal:  Perm J       Date:  2018

5.  Uric Acid and CKD Progression Matures with Lessons for CKD Risk Factor Discovery.

Authors:  Oluwaseun Oluwo; Julia J Scialla
Journal:  Clin J Am Soc Nephrol       Date:  2020-10-14       Impact factor: 8.237

Review 6.  Renal effects of SGLT2 inhibitors: an update.

Authors:  Josselin Nespoux; Volker Vallon
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-03       Impact factor: 3.416

7.  Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.

Authors:  Brendon L Neuen; Toshiaki Ohkuma; Bruce Neal; David R Matthews; Dick de Zeeuw; Kenneth W Mahaffey; Greg Fulcher; Mehul Desai; Qiang Li; Hsiaowei Deng; Norm Rosenthal; Meg J Jardine; George Bakris; Vlado Perkovic
Journal:  Circulation       Date:  2018-10-09       Impact factor: 29.690

Review 8.  Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease.

Authors:  Sebastian Niezen; Humberto Diaz Del Castillo; Lumen A Mendez Castaner; Alessia Fornoni
Journal:  Endocrinol Diabetes Metab       Date:  2019-05-17

9.  How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area.

Authors:  Silvia Canivell; Manel Mata-Cases; Bogdan Vlacho; Mònica Gratacòs; Jordi Real; Dídac Mauricio; Josep Franch-Nadal
Journal:  J Diabetes Res       Date:  2019-11-11       Impact factor: 4.011

10.  The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis.

Authors:  Rosalie A Scholtes; Daniël H van Raalte; Ricardo Correa-Rotter; Robert D Toto; Hiddo J L Heerspink; Valerie Cain; C David Sjöström; Peter Sartipy; Bergur V Stefánsson
Journal:  Diabetes Obes Metab       Date:  2019-12-14       Impact factor: 6.577
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.